• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
Generic Name:  ansuvimab
Date Designated:  03/30/2020
Orphan Designation:  Post-exposure prophylaxis against Ebola virus infection
Orphan Designation Status:  Designated
FDA Orphan Approval Status:  Not FDA Approved for Orphan Indication
Ridgeback Biotherapeutics LP
3162 Commodore Plaza
Suite 3E
Miami, Florida 33133-
United States

The sponsor address listed is the last reported by the sponsor to OOPD.
*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.